Observational study / 2011
Antibodies against Mycobacterium avium paratuberculosis were linked to cross-reactivity with the beta-cell antigen ZnT8 in Sardinian type 1 diabetes patients.
Researchers analyzed antibody responses against the Mycobacterium avium subspecies paratuberculosis (MAP) protein MAP3865c and its cross-reactivity with the beta-cell protein ZnT8 in Sardinian T1D, T2D, and healthy subjects using an enzymatic immunoassay. Antibodies against MAP3865c recognized two immunodominant transmembrane epitopes in 52-65% of T1D patients, compared with 5-7% of T2D patients and 3-5% of healthy controls. Titers of anti-MAP3865c and anti-ZnT8 antibodies targeting these homologous epitopes correlated linearly, and pre-incubation with ZnT8 epitope peptides blocked binding to MAP3865c peptides.
Shows an association, not proof of cause and effect.
- Study type
- Case-control study
- Who was studied
- Sardinian patients with type 1 diabetes (T1D), type 2 diabetes (T2D), and healthy controls
- What was measured
- Antibody responses and cross-reactivity against MAP3865c and ZnT8 epitopes
THE PAPER
Antibodies recognizing Mycobacterium avium paratuberculosis epitopes cross-react with the beta-cell antigen ZnT8 in Sardinian type 1 diabetic patients.
Masala S, Paccagnini D, Cossu D, Brezar V, Pacifico A, Ahmed N, Mallone R, Sechi LA. PLoS One, 2011.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.